Panel of 15 potent antibodies selected that are optimally suited to clinical development and manufacturing
Monoclonal antibodies have the potential to both treat infected patients and provide protection to the “at risk” population during the pandemic
Viral neutralization data independently verified by the National Institute for Biological Standards and Control (NIBSC)
Project is part of an industry-wide collaboration under the BioIndustry Association’s antibody taskforce
IONTAS and FairJourney Biologics, two leading antibody discovery Clinical Research Organisations (CROs) that joined forces this year, today announce the discovery of potent SARS-CoV2 neutralizing antibodies as potential therapeutics for COVID-19.
The newly-identified panel of antibodies have been shown to block infection at doses as low as 20pM in pseudoviral assays and 100pM in live coronavirus assays, surpassing or matching the best antibodies reported. This viral neutralization efficiency was independently verified by the National Institute for Biological Standards and Control (NIBSC), a key player in assuring